2 November 2020 - DBV Technologies today announced that its marketing authorisation application for its investigational product Viaskin Peanut (DBV712) has been validated by the EMA. 

The validation of the application confirms that the submission is sufficiently complete to begin the formal review process for the investigational non-invasive, once-daily epicutaneous patch to treat peanut allergies in children ages 4 to 11 years.

Read DBV Technologies press release